Search Results
Your search for Neal Ready, MD, PhD,Neal Ready, MD, PhD matches 3 pages
Showing 1 - 3Incorporating Immunotherapy Into Treatment of Early-Stage NSCLC
There is a strong rationale for incorporating immunotherapy into the treatment of early-stage non–small cell lung cancer (NSCLC), given the breakthrough results with PD-1 checkpoint inhibitors as monotherapy, combined with immunotherapy, or combined with chemotherapy in advanced-stage NSCLC. As...
Nivolumab Plus Ipilimumab in Advanced NSCLC: Outcomes by PD-L1 and Tumor Mutational Burden Status
As reported in the Journal of Clinical Oncology by Ready et al, the phase II CheckMate 568 trial has shown that higher tumor mutational burden is associated with response, irrespective of programmed cell death ligand 1 (PD-L1) expression in first-line nivolumab plus low-dose ipilimumab treatment of ...
Maintenance Sunitinib Improves Progression-Free Survival in Phase II Trial in Untreated Extensive-Stage Small Cell Lung Cancer
In the randomized phase II Cancer and Leukemia Group B (CALGB) 30504/Alliance trial reported in the Journal of Clinical Oncology, Ready et al found that sunitinib (Sutent) vs placebo maintenance following chemotherapy improved progression-free survival in patients with previously untreated...
